Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Seizure Reduction And Cognitive Improvements In Dravet Syndrome
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Seizure Reduction And Cognitive Improvements In Dravet Syndrome
stoke therapeutics發佈數據，顯示Zorevunersen顯著減少癲癇發作並改善Dravet綜合徵認知能力
- – New data showed improvements in cognition and behavior during the first year of treatment with additional increases demonstrated as treatment continued –
- – Clinical effects observed across the Phase 1/2a and open-label extension studies (OLEs) of zorevunersen are a first in the treatment of Dravet syndrome and support plans for the Company's Phase 3 registrational study –
- – Zorevunersen generally well-tolerated across the studies –
- – Data presented for the first time at the 15th European Epilepsy Congress (EEC) –
- — 新數據顯示，在治療的第一年中，認知和行爲有所改善，隨着治療的繼續，認知和行爲也有所改善 —
- — 在zorevunersen的1/2a期和開放標籤擴展研究（OLE）中觀察到的臨床效果是Dravet綜合徵治療的首例，也是該公司3期註冊研究的支持計劃—
- — Zorevunersen 在整個研究中普遍耐受性良好 —
- — 在第十五屆歐洲癲癇大會（EEC）上首次公佈的數據 —